Triple-negative breast cancer: therapeutic options.

By Susan J. Cleator, W. Heller, R. Coombes. The Lancet Oncology, 2007

875 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/38a85fa88a446a8d74afd5b87ac649ac3388fb9c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Mark J. O'Connor

In Molecular Biology

1. Mark J. O'Connor

Citations in the corpus

• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (2008, background): “In particular, treatment of patients with triple-negative breast cancers, which account for 15% of all breast cancers (19) and frequently harbor BRCA1 pathway defects (20–23), might be useful, because no targeted therapy exists thus far for this subgroup of breast cancers.”